Errata (DOI:10.1016/S1470-2045(09)70334-1);Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

The Lancet Oncology

Volumn 11, Issue 2, 2010, Pages 155-164

  Wolchok, Jedd D ^a   Neyns, Bart ^b   Linette, Gerald ^c   Negrier, Sylvie ^d   Lutzky, Jose ^e   Thomas, Luc ^f   Waterfield, William ^g   Schadendorf, Dirk ^h   Smylie, Michael ⁱ   Guthrie Jr , Troy ^j   Grob, Jean Jacques ^k   Chesney, Jason ^l   Chin, Kevin ^m   Chen, Kun ^m   Hoos, Axel ^m   O'Day, Steven J ⁿ   Lebbé, Celeste ^o  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e Mount Sinai Comprehensive Cancer Center   (United States)

^f UNIVERSITÉ DE LYON   (France)

^g Weinberg Cancer Institute   (United States)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j Baptist Cancer Institute   (United States)

^k HÔPITAL SAINTE MARGUERITE   (France)

^l UNIVERSITY OF LOUISVILLE   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ Medical Oncology   (United States)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; STEROID; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COLITIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; INOPERABLE CANCER; LIVER DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; VOMITING;

EID: 75249100054     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70048-6     Document Type: Erratum

References (31)

1. Tsao H., Atkins M.B., and Sober A.J. Management of cutaneous melanoma. N Engl J Med 351 (2004) 998-1012
2. Tarhini A.A., and Agarwala S.S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19 (2006) 19-25
3. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
4. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105-2116
5. Sasse A.D., Sasse E.C., Clark L., Ulloa L., and Clark O. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 1 (2007) CD005413.
6. Korman A., Yellin M., and Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6 (2005) 582-591
7. Langer L.F., Clay T.M., and Morse M.A. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7 (2007) 1245-1256
8. O'Day S.J., Hamid O., and Urba W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110 (2007) 2614-2627
9. Peggs K.S., Quezada S.A., Korman A.J., and Allison J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18 (2006) 206-213
10. Fong L., and Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26 (2008) 5275-5283
11. Kwon E.D., Hurwitz A.A., Foster B.A., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94 (1997) 8099-8103
12. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
13. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58 (2009) 823-830
14. O'Day SJ, Ibrahim R, DePril V, et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. 2008 ASCO Annual Meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 9021.
15. Hersh EM, Weber JS, Powderly JD, et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. 2008 ASCO Annual Meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 9022.
16. Downey S.G., Klapper J.A., Smith F.O., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13 (2007) 6681-6688
17. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12 (2005) 1005-1016
18. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 (2003) 4712-4717
19. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
20. Weber J.S., O'Day S., Urba W., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26 (2008) 5950-5956
21. Weber J., Thompson J.A., Hamid O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15 (2009) 5591-5598
22. ClinicalTrials.gov. Study of ipilimumab (MDX-010) monotherapy in patients with previously treated unresectable stage III or IV melanoma. http://clinicaltrials.gov/ct2/show/NCT00289640 (accessed Oct 23, 2009).
23. ClinicalTrials.gov. A companion study for patients enrolled in prior/parent ipilimumab studies. http://clinicaltrials.gov/show/NCT00162123 (accessed Oct 23, 2009).
24. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related Response Criteria. Clin Cancer Res 15 (2009) 7412-7420
25. Clopper C.J., and Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26 (1934) 404-413
26. Corcoran C.D., and Mehta C.R. Exact level and power of permutation, bootstrap and asymptotic tests of trend. J Mod Appl Stat Meth 1 (2002) 42-51
27. Brookmeyer R., and Crowley J. A confidence interval for the median survival time. Biometrics 38 (1982) 29-41
28. ClinicalTrials.gov. Phase II study to determine predictive markers of response to BMS-734016 (MDX-010). http://clinicaltrials.gov/show/NCT00261365 (accessed Nov 24, 2009).
29. Amin A, DePril V, Hamid O, et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. 2009 ASCO Annual Meeting; Orlando, FL, USA; May 29-June 2, 2009. Abstract 9037.
30. Korn E.L., Liu P.Y., Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26 (2008) 527-534
31. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. 2008 ASCO Annual Meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 9063.